Vijayakrishna Gadi, MD, University of Illinois College of Medicine
Articles by Vijayakrishna Gadi, MD, University of Illinois College of Medicine
Managing Toxicities in Short- and Long-Term Treatment with ADCs
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.
Managing ILD and Pneumonitis Risk From ADCs
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.
The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.
Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD A panel of experts discuss the challenges of testing for HER2-low access solid tumor types.
ADCs Targeting HER2+ GU Cancers
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD A panel of experts discuss if there is a role for HER2-directed ADCs antibody-drug conjugates in GU genitourinary cancers
Impact of ADCs on Brain Metastases
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm.
ADCs Targeting HER2+ Lung Cancer
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.
Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.
ADCs Targeting GI Cancers
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.
ADCs Targeting HER2+ Gynecologic Cancers
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.
ADCs Targeting HER2+ Breast Cancer
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.
Assessing HER2 Status Across Tumor Types
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss ongoing research efforts in HER2-positive early breast cancer.
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss unmet needs in the treatment of patients with HER2-positive early breast cancer.
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.
Using Systemic Therapy to Treat HER2+ Breast Cancer
ByLisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center ,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.
Emerging Therapies for HER2+ MBC
ByLisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center ,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute An overview of therapies under study in later-stage clinical trials to treat HER2-positive metastatic breast cancer.
Immunotherapy for HER2+ Breast Cancer
ByLisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center ,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute The rationale for incorporating checkpoint inhibitors into treatment regimens for HER2-positive breast cancer.
Emerging Combinations for Triple-Positive Breast Cancer
ByLisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center ,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute An overview of various trials investigating combination approaches as frontline therapy for triple-positive breast cancer and considerations for when to use chemotherapy and bring endocrine therapy into treatment.
Frontline Therapy for Triple-Positive Breast Cancer
ByLisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center ,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute Vijayakrishna Gadi, MD, PhD, defines triple-positive breast cancer and reacts to the potential use of trastuzumab combined with endocrine therapy as frontline therapy.
Gaps in Treatment for HER2+ MBC With Brain Metastasis
ByLisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center ,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute Considerations for addressing gaps in treatment for patients with HER2-positive metastatic breast cancer and brain metastasis, based on recent trial data.
Case Scenario: 55-Year-Old Woman With HER2+ MBC and Brain Metastasis
ByLisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center ,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute A discussion regarding the preferred treatment approach for a 55-year-old woman with HR-/HER2+ metastatic breast cancer and 2 brain metastases.
Treatment Options for HER2+ MBC With Brain Metastasis
ByLisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center ,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute Options available to treat patients with HER2-positive metastatic breast cancer and brain metastasis, and factors that impact choice of therapy based on CNS data demonstrated in several clinical trials of HER2-targeted agents.
Brain Metastasis in HER2+ MBC
ByLisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center ,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute Recommendations for screening patients with HER2-positive metastatic breast cancer for signs of brain metastasis as a consequence of current rates of prevalence.
Relapsed/Refractory HER2+ MBC Treatment Decisions
ByLisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center ,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute Options available to treat patients with HER2-positive metastatic breast cancer following frontline therapy with T-DM1.
Individualized Treatment Decisions for HER2+ Breast Cancer
ByLisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center ,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute Variables that breast oncologists need to consider when selecting an appropriate systemic treatment approach for a patient with HER2-positive breast cancer.
Subcutaneous Therapy for HER2+ Breast Cancer
ByLisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center ,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute Breast oncologists discuss the pros and cons of treating patients with HER2-postive breast cancer with the fixed-dose subcutaneous formulation of pertuzumab plus trastuzumab compared with IV chemotherapy.
Gaps in Treatment for HER2+ MBC With Brain Metastasis
Subcutaneous Therapy for HER2+ Breast Cancer
Updates in HER2+ MBC: The NALA and SOPHIA Trials
ADCs Targeting HER2+ Lung Cancer
Individualized Treatment Decisions for HER2+ Breast Cancer